Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...